Abstract
Somatic gene therapy is supposed to cure life-threatening hematopoietic disorders but is limited by unstable transgene expression. Efficient gene transfer to hematopoietic progenitor cells does not ensure long-term gene expression. It would therefore be advantageous if the expression of transgenes could be restored in bone marrow. Transfer of drug resistance genes such as the multidrug resistance (MDR1) or mutated dihydrofolate reductase (DHFR) genes to hematopoietic cells protects them from the toxicity of anticancer drugs. In addition, transduced cells obtain a selective growth advantage in the presence of anticancer drugs. This can be used to introduce and enrich otherwise non-selectable genes by cotransfer to target cells. Bicistronic vectors have been constructed for coexpression of drug resistance genes and non-selectable, therapeutic genes with the use of an internal ribosomal entry-site (IRES). With the use of bicistronic vectors, expression and function of therapeutic genes hav e been increased in tissue culture and in animal models. Further preclinical investigations are needed to identify optimal conditions for selection.
Keywords: Hematopoietic Cells, Transgene Expression
Current Gene Therapy
Title: Restoration of Transgene Expression in Hematopoietic Cells with Drug-Selectable Marker Genes
Volume: 2 Issue: 2
Author(s): Thomas Licht and Chrisitian Peschel
Affiliation:
Keywords: Hematopoietic Cells, Transgene Expression
Abstract: Somatic gene therapy is supposed to cure life-threatening hematopoietic disorders but is limited by unstable transgene expression. Efficient gene transfer to hematopoietic progenitor cells does not ensure long-term gene expression. It would therefore be advantageous if the expression of transgenes could be restored in bone marrow. Transfer of drug resistance genes such as the multidrug resistance (MDR1) or mutated dihydrofolate reductase (DHFR) genes to hematopoietic cells protects them from the toxicity of anticancer drugs. In addition, transduced cells obtain a selective growth advantage in the presence of anticancer drugs. This can be used to introduce and enrich otherwise non-selectable genes by cotransfer to target cells. Bicistronic vectors have been constructed for coexpression of drug resistance genes and non-selectable, therapeutic genes with the use of an internal ribosomal entry-site (IRES). With the use of bicistronic vectors, expression and function of therapeutic genes hav e been increased in tissue culture and in animal models. Further preclinical investigations are needed to identify optimal conditions for selection.
Export Options
About this article
Cite this article as:
Licht Thomas and Peschel Chrisitian, Restoration of Transgene Expression in Hematopoietic Cells with Drug-Selectable Marker Genes, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605636
DOI https://dx.doi.org/10.2174/1566523024605636 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Progress in Chemo- and Regioselective Transformations of Symmetrical Cephalostatin Analogues
Letters in Organic Chemistry Effects of Polymorphisms of the CYP450 Enzyme Genes on Estrogen Status and the Risk for Osteoporosis
Current Pharmacogenomics Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Specific Immune Intervention with Monoclonal Antibodies for the Treatment of Multiple Sclerosis
Current Medicinal Chemistry Role of Human and Mouse HspB1 in Metastasis
Current Molecular Medicine Recent Advances and Strategies in Tumor Vasculature Targeted Nano-Drug Delivery Systems
Current Pharmaceutical Design Difference Gel Electrophoresis: Application in Quantitative Proteomics Research
Current Proteomics The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Dietary Manipulation of Precursor Polyunsaturated Fatty Acids Modulates Eicosanoid and Endocannabinoid Synthesis: A Potential Tool to Control Tumor Development
Current Nutrition & Food Science Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science Targeting the Atypical Chemokine Receptor ACKR3/CXCR7: Phase 1 - Phage Display Peptide Identification and Characterization
Current Topics in Medicinal Chemistry Treatment and Response to Statins: Gender-related Differences
Current Medicinal Chemistry Current Treatment Concepts of CML
Current Cancer Drug Targets Pharmacokinetics of CNT-based Drug Delivery Systems
Current Drug Metabolism Neurological Aspects of Grief
CNS & Neurological Disorders - Drug Targets DIMming Ovarian Cancer Growth
Current Drug Targets Understanding the Potential Role and Delivery Approaches of Nitric Oxide in Chronic Wound Healing Management
Current Pharmaceutical Design